Enlaza Therapeutics Inc. will take charge of research through nominating candidates in its potentially $2 billion-plus deal with Vertex Pharmaceuticals Inc. For its efforts, Enlaza is getting $45 ...

Vertex Pharmaceuticals Incorporated just experienced a notable drop in its market position. Investors are buzzing, trying to ...

Vertex Pharmaceuticals Incorporated faces a dynamic landscape with its innovative approach in the pharmaceutical industry. As challenges mount in a competitive sector, the company taps into its ...

DM1 results from a CTG repeat expansion in the DMPK gene, with disease severity linked to the number of repeats (symptoms ...

Trinasolar, a global leader in solar technology and energy storage solutions, will showcase the next chapter of its U.S. innovation at RE+ ...

A federal judge ruled Hampton’s Zoning Board had ample evidence to reject the tower, but left one legal claim standing.

Vertex stock falls after pain drug VX-993 fails Phase 2 trial, despite better-than-expected Q2 earnings and strong cystic fibrosis drug sales.

A next-generation Vertex Pharmaceuticals pain drug failed to beat a placebo in a Phase 2 clinical trial. Despite the disappointing outcome in bunionectomy pain, the company is continuing ...

Vertex narrows near-term development plan for Journavx after FDA naysays broad label in neuropathic pain By Fraiser Kansteiner Aug 5, 2025 10:55am Vertex Pharmaceuticals Journavx pain drug chronic ...

Vertex Pharmaceuticals (VRTX) falls premarket as VX-993 fails Phase 2 pain study endpoint.

Vertex Pharmaceuticals will stop developing its experimental non-opioid painkiller as a solo treatment after a mid-stage trial failure and will not start a study for expanded use of its approved ...